Class: First Generation Antihistamines
ATC Class: D04AA32
VA Class: AH200
CAS Number: 88637-37-0
Brands: Alka-Seltzer PM, AllerMax, Bayer PM, Benadryl, Benadryl Allergy, Compoz, Diphenhist, Doan's P.M., Excedrin P.M. , Genahist, Goody's PM Powder, Hydramine, Legatrin PM, Nighttime Sleep Aid, Nytol , Percogesic, Simply Sleep , Sine-Off , Sleepinal, Sominex, Sudafed, Tylenol Allergy, Tylenol PM , Twilite, Unisom
Special Alerts:
[Posted 01/13/2011] ISSUE: FDA notified healthcare professionals that it has asked drug manufacturers to limit the strength of acetaminophen in prescription drug products, predominantly combinations of acetaminophen and opioids, to 325 mg per tablet, capsule, or other dosage unit, making these products safer for patients. This action will help to reduce the risk of severe liver injury and allergic reactions associated with acetaminophen. A Boxed Warning highlighting the potential for severe liver injury and a Warning highlighting the potential for allergic reactions (swelling of the face, mouth, and throat, difficulty breathing, itching, or rash) will be added to the label of all prescription drug products that contain acetaminophen.
BACKGROUND: Acetaminophen, one of the most commonly used drugs in the United States, is widely and effectively used in both prescription and over-the-counter (OTC) products to reduce pain and fever. Examples of prescription products that contain acetaminophen include hydrocodone with acetaminophen (Vicodin, Lortab), and oxycodone with acetaminophen (Tylox, Percocet). OTC products containing acetaminophen (e.g., Tylenol) are not affected by this action. Information about the potential for liver injury is already required on the label for OTC products containing acetaminophen. FDA is continuing to evaluate ways to reduce the risk of acetaminophen related liver injury from OTC products. No drug shortages are expected, because the 3-year implementation period should permit adequate time for necessary reformulations.
RECOMMENDATION: Healthcare professionals were reminded to advise patients not to exceed the acetaminophen maximum total daily dose (4 grams/day), and not to drink alcohol while taking acetaminophen-containing medications.
Healthcare professionals were encouraged to inform patients that there is no immediate danger to patients who take these combination pain medications, and patients should continue to take them as directed by their health care provider. The Drug Safety Communication provides additional information for healthcare professionals, information for patients, a data summary and a list of all affected products. For more information visit the FDA website at: and .
Introduction
First generation antihistamine; an ethanolamine-derivative.a
Uses for Diphenhydramine Hydrochloride
Acute Allergic Reactions
Amelioration of allergic reactions to blood or plasma.101
Adjunct to epinephrine and other standard measures for management of anaphylaxis after acute symptoms have been controlled.101 102 103
Used IV or IM for management of other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.101
Allergic Rhinitis
Self-medication for temporary relief of rhinorrhea, sneezing, lacrimation, itching eyes, oronasopharyngeal irritation or itching, or cough associated with allergic rhinitis (e.g., hay fever) or other upper respiratory allergies.
Used in fixed combination with other agents (e.g., acetaminophen, phenylephrine, pseudoephedrine) for relief of rhinorrhea, sneezing, lacrimation, itching eyes, oronasopharyngeal itching, and/or other symptoms (e.g., headache, nasal/sinus congestion) associated with seasonal or perennial allergic rhinitis or other upper respiratory allergies.110 112 114
Use fixed-combination preparations only when symptoms amenable to each ingredient are present concurrently.
Common Cold
Self-medication for temporary relief of symptoms associated with the common cold (e.g., rhinorrhea, sneezing, cough).
Used in fixed combination with other agents (e.g., acetaminophen, phenylephrine, pseudoephedrine) for symptomatic relief of rhinorrhea, sneezing, and/or other symptoms associated with the common cold (e.g., headache, minor aches and pains, sore throat, cough, nasal congestion).108 112 114
Insomnia
Self-medication for short-term (i.e., ≤2 weeks) management of occasional sleeplessness, particularly in individuals who have difficulty falling asleep.104
Used in fixed combination with other agents (e.g., acetaminophen, aspirin) for short-term management of occasional sleeplessness.107 109 111 113
Development of tolerance reported with repeated use.104
Dermatologic Disorders
Systemic antihistamines may be more effective than topical, especially if pruritus is generalized, and less likely to cause sensitivity reactions than when applied topically for pruritus associated with various dermatologic conditions.
Motion Sickness
Prevention and treatment of nausea, vomiting, and/or vertigo associated with motion sickness.101
Parkinsonian Syndrome
May be useful as alternative therapy in the management of tremor early in the course of parkinsonian syndrome. Also may be useful in the management of drug-induced extrapyramidal reactions.
Used IV for management of parkinsonian syndrome when oral therapy is impossible or contraindicated.101 Used specifically in geriatric patients who are unable to tolerate more potent agents; for mild cases of parkinsonism in younger patients; and in combination with centrally acting anticholinergic agents in other cases of parkinsonism.101
Diphenhydramine Hydrochloride Dosage and Administration
Administration
Administer diphenhydramine hydrochloride orally or by IV or deep IM injection.a
Administer diphenhydramine citrate-containing preparations orally.a
Oral Administration
Diphenhydramine hydrochloride chewable tablets: Chew thoroughly before swallowing.a
Diphenhydramine citrate orally disintegrating tablets: Place tablet on the tongue, allow tablet to disintegrate (within a few seconds), then swallow with or without water.a
IV Administration
For solution and drug compatibility information, see Compatibility under Stability.
IV injection preferred over deep IM injection.a
IV use in a home-care setting should be employed under careful supervision.a
Rate of Administration
≤25 mg/minute.
Dosage
Available as diphenhydramine hydrochloride and diphenhydramine citrate; dosage is expressed in terms of diphenhydramine hydrochloride or diphenhydramine citrate.a
Diphenhydramine citrate available only in fixed-combination preparations.a
12.5 mg diphenhydramine hydrochloride equivalent to 19 mg diphenhydramine citrate.a
Fixed-combination preparations do not permit individual titration of dosages. When used in fixed combination with other agents (e.g., acetaminophen, aspirin, phenylephrine, pseudoephedrine), select a dosage that is within the usual therapeutic range for each ingredient. Because combinations and dosage strengths vary for fixed-combination preparations, consult manufacturer's product labeling for appropriate dosage of the specific preparation.
Pediatric Patients
Allergic Conditions and the Common Cold
Acute Allergic Reactions
IV or IM
Children >1 month of age: 5 mg/kg daily or 150 mg/m2 daily (up to a maximum of 300 mg daily) divided in 4 doses.
Alternatively, 1–2 mg/kg recommended by some experts.102 103
Allergic Rhinitis and the Common Cold
Oral
Self-medication in children 2–5 years of age: 6.25 mg every 4–6 hours (as diphenhydramine hydrochloride) or 9.5 mg every 4 hours (as diphenhydramine citrate) when directed by a clinician; do not exceed 37.5 mg (as diphenhydramine hydrochloride) or 57 mg (as diphenhydramine citrate) in 24 hours. (See Pediatric Use under Cautions.)
Self-medication in children 6–11 years of age: 12.5–25 mg every 4–6 hours (as diphenhydramine hydrochloride) or 19 mg every 4 hours (as diphenhydramine citrate); do not exceed 150 mg (as diphenhydramine hydrochloride) or 76 mg (as diphenhydramine citrate) in 24 hours.
Self-medication in children ≥12 years of age: 25–50 mg every 4–6 hours (as diphenhydramine hydrochloride) or 38 mg every 4 hours (as diphenhydramine citrate); do not exceed 300 mg (as diphenhydramine hydrochloride) or 152 mg (as diphenhydramine citrate) in 24 hours.
Insomnia
Oral
Children 2–11 years of age†: 1 mg/kg (as diphenhydramine hydrochloride) 30 minutes before retiring; do not exceed 50 mg.
Self-medication in children ≥12 years of age: 50 mg (as diphenhydramine hydrochloride) or 76 mg (as diphenhydramine citrate) at bedtime as needed, or as directed by a clinician. Higher dosages do not produce substantially greater benefit but may be associated with a higher incidence of adverse (e.g., anticholinergic) effects.
Use not recommended for ≥7–10 nights.104
Motion Sickness
Oral
Children 2–5 years of age†: 6.25 mg (as diphenhydramine hydrochloride) 30–60 minutes before travel and every 4–6 hours during travel; do not exceed 37.5 mg in 24 hours.105
Self-medication in children 6–11 years of age: 12.5–25 mg (as diphenhydramine hydrochloride) 30–60 minutes before travel and every 4–6 hours during travel; do not exceed 150 mg in 24 hours.105
Self-medication in children ≥12 years of age: 25–50 mg (as diphenhydramine hydrochloride) 30 minutes before exposure to motion and then every 4–6 hours (before meals and at bedtime) for duration of exposure; do not exceed 300 mg in 24 hours.
IV or IM
Children >1 month of age: 5 mg/kg daily or 150 mg/m2 daily (up to a maximum of 300 mg daily) divided in 4 doses.
Parkinsonian Syndrome
IV or IM
Children >1 month of age: 5 mg/kg daily or 150 mg/m2 daily (up to a maximum of 300 mg daily) divided in 4 doses.
Adults
Allergic Conditions and the Common Cold
Acute Allergic Reactions
IV or IM
10–50 mg; in a few patients, up to 100 mg may be required.
Alternatively, 25–50 mg recommended by some experts.102 103
Allergic Rhinitis and the Common Cold
Oral
Self-medication: 25–50 mg every 4–6 hours (as diphenhydramine hydrochloride) or 38 mg every 4 hours (as diphenhydramine citrate); do not exceed 300 mg (as diphenhydramine hydrochloride) or 152 mg (as diphenhydramine citrate) in 24 hours.
Insomnia
Oral
Self-medication: 50 mg (as diphenhydramine hydrochloride) or 76 mg (as diphenhydramine citrate) at bedtime as needed, or as directed by a clinician. Higher dosages do not produce substantially greater benefit but may be associated with a higher incidence of adverse (e.g., anticholinergic) effects.
Use not recommended for ≥7–10 nights.104
Motion Sickness
Oral
Self-medication: 25–50 mg (as diphenhydramine hydrochloride) 30 minutes before exposure to motion and then every 4–6 hours (before meals and at bedtime) for duration of exposure; do not exceed 300 mg in 24 hours.
IV or IM
10–50 mg; in a few patients, up to 100 mg may be required.
Parkinsonian Syndrome
Oral
Initially, 25 mg 3 times daily (as diphenhydramine hydrochloride).a If necessary, gradually increase dosage to 50 mg 4 times daily.a
IV or IM
10–50 mg; in a few patients, up to 100 mg may be required.
Prescribing Limits
Pediatric Patients
Oral
Children 2–5 years of age: Maximum 37.5 mg (as diphenhydramine hydrochloride) or 57 mg (as diphenhydramine citrate) in 24 hours. (See Pediatric Use under Cautions.)
Children 6–11 years of age: Maximum 150 mg (as diphenhydramine hydrochloride) or 76 mg (as diphenhydramine citrate) in 24 hours.
Children ≥12 years of age: Maximum 300 mg (as diphenhydramine hydrochloride) or 152 mg (as diphenhydramine citrate) in 24 hours.
IV or IM
Children >1 month: Maximum 300 mg daily.101
Adults
Oral
Maximum 300 mg in 24 hours.
IV or IM
Maximum 400 mg daily.101
Cautions for Diphenhydramine Hydrochloride
Contraindications
Use contraindicated in neonates and premature infants.101 (See Pediatric Use under Cautions.)
Women who are breast-feeding.101 (See Lactation under Cautions.)
Injection should not be used as a local anesthetic.101 (See Local Necrosis under Cautions.)
Concomitant use with other preparations containing diphenhydramine, including oral and topical preparations.
Known hypersensitivity to diphenhydramine, other antihistamines with similar chemical structure, or any ingredient in the formulation.
Warnings/Precautions
Warnings
Concomitant Diseases
Patients with glaucoma, respiratory conditions (e.g., emphysema, chronic bronchitis), or difficulty urinating due to prostatic hypertrophy should consult a clinician before initiating therapy with diphenhydramine.
Use with caution in patients with increased IOP, angle-closure glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, bladder-neck obstruction, symptomatic prostatic hypertrophy, active or a history of lower respiratory disease (e.g., bronchial asthma), hyperthyroidism, or cardiovascular disease (e.g., hypertension).
CNS Effects
Risk of marked drowsiness. Among first generation antihistamines, ethanolamines (e.g., diphenhydramine) considered the most sedating106 c and alkylamines (e.g., brompheniramine, chlorpheniramine) considered the least sedating.106
Possible excitability (especially in children).
Caution when driving a motor vehicle, operating machinery, or engaging in other potentially hazardous tasks.c (See CNS Depressants under Interactions.)
Diphenhydramine Toxicity
Risk of toxicity. (See Pediatric Use under Cautions.) Do not use more often than directed for any condition; do not concomitantly use more than one preparation containing diphenhydramine (e.g., avoid simultaneous use of oral and topical preparations).
Local Necrosis
Risk of local necrosis with subcutaneous or intradermal administration. Do not use diphenhydramine injection as a local anesthetic.
Sensitivity Reactions
Sulfite Sensitivity
Some formulations may contain sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.a
General Precautions
Duration of Therapy
When used for insomnia, avoid using for self-medication for longer than 7–10 nights,104 and consult a clinician if insomnia persists continuously for >2 weeks.
Phenylketonuria
Certain preparations (e.g., Alka-Seltzer PM, Benadryl chewable tablets; Children's Benadryl Allergy & Sinus Fastmelt orally disintegrating tablets) contain aspartame (NutraSweet) which is metabolized in the GI tract to phenylalanine following oral administration.113 114 a
Use of Fixed Combinations
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
When used in fixed combination with other agents (e.g., acetaminophen, aspirin, phenylephrine, pseudoephedrine), consider the cautions, precautions, and contraindications associated with the concomitant agent(s).107 108 109 110 111 112 113 114
Specific Populations
Pregnancy
Category B.
Lactation
Has been detected in milk. Discontinue nursing or the drug because of potential risk to nursing infants.
Pediatric Use
Risk of diminished mental alertness. Risk of excitation in young pediatric patients.
Risk of diphenhydramine toxicity (e.g., dilated pupils, flushed face, hallucinations, ataxic gait, urinary retention) when oral preparations used concomitantly with topical preparations of diphenhydramine. (See Diphenhydramine Toxicity under Cautions.)
Potential for misuse and abuse following parenteral administration over a prolonged period of time.
Use with caution in infants and young children; should not be used in premature or full-term neonates. Children <6 years of age should receive oral diphenhydramine only under the direction of a physician.
Safety and efficacy of diphenhydramine as a nighttime sleep aid in children <12 years of age have not been established. Consider risk of possible CNS stimulation when used as nighttime sleep aids.
Risk of overdosage and toxicity (including death) in children <2 years of age receiving OTC preparations containing antihistamines, cough suppressants, expectorants, and nasal decongestants alone or in combination for relief of symptoms of upper respiratory tract infection. Limited evidence of efficacy for these preparations in this age group; appropriate dosages not established. Therefore, FDA recommended not to use such preparations in children <2 years of age; safety and efficacy in older children currently under evaluation. Because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations recently agreed to voluntarily revise the product labeling to state that such preparations should not be used in children <4 years of age. During the transition period, some preparations on pharmacy shelves will have the new recommendation (“do not use in children <4 years of age”), while others will have the previous recommendation (“do not use in children <2 years of age”). FDA recommends that parents and caregivers adhere to dosage instructions and warnings on the product labeling that accompanies the preparation and consult a clinician about any concerns. Clinicians should ask caregivers about use of OTC cough/cold preparations to avoid overdosage.
Geriatric Use
Possible increased risk of dizziness, sedation, and hypotension in patients ≥60 years of age.
Common Adverse Effects
Sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, thickening of bronchial secretions.
Interactions for Diphenhydramine Hydrochloride
CNS Depressants
Potential pharmacologic interaction (additive CNS depression) with alcohol and other CNS depressants (e.g., hypnotics, sedatives, tranquilizers).
Laboratory Test Interferences
Antihistamines may suppress inhalation-challenge testing with histamine or antigen as well as the wheal and flare reactions to antigen skin testing.
Specific Drugs
Drug | Interaction |
|---|---|
MAO inhibitors | MAO inhibitors prolong and intensify anticholinergic effects of antihistamines |
Diphenhydramine Hydrochloride Pharmacokinetics
Absorption
Bioavailability
Well absorbed following oral administration, but only about 40–60% of an oral dose reaches systemic circulation as unchanged drug.
Onset
Appears in plasma within 15 minutes following oral administration of a single dose; peak plasma concentrations are attained within 1–4 hours.
Antihistamine effect peaks within 1–3 hours and persists for up to 7 hours after administration of a single dose.
Sedative effects peak within 1–3 hours after administration of a single dose.
Distribution
Extent
Highest concentrations detected in the lungs, spleen, and brain in rats; small amounts detected in the heart, muscle, and liver.
Crosses the placenta and has been detected in milk, although the extent of distribution into milk has not been quantitated.
Plasma Protein Binding
Approximately 80–85%.
Special Populations
Larger volume of distribution in Asian adults (about 480 L) than in white adults (188–336 L).
Less extensive protein binding reported in healthy Asian adults and in adults with liver cirrhosis.
Elimination
Metabolism
Rapidly and apparently almost completely metabolized.
Undergoes substantial first-pass metabolism in the liver following oral administration.
Elimination Route
Excreted in urine (50–75%) mainly as metabolites.
Half-Life
2.4–9.3 hours in healthy adults.
Special Populations
Terminal elimination half-life is prolonged in adults with liver cirrhosis.
Stability
Storage
Oral
Capsules and Tablets
15–25°C. Protect from heat, light, and moisture.
Parenteral
Injection
15–30°C. Protect from freezing and light.
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Parenteral
Solution CompatibilityHID
Compatible |
|---|
Dextran 6% in dextrose 5% |
Dextran 6% in sodium chloride 0.9% |
Dextrose–Ringer’s injection combinations |
Dextrose–Ringer’s injection, lactated, combinations |
Dextrose–saline combinations |
Dextrose 2.5, 5, or 10% in water |
Fat emulsion 10%, intravenous |
Fructose 10% in sodium chloride 0.9% |
Fructose 10% in water |
Invert sugar 5 and 10% in sodium chloride 0.9% |
Invert sugar 5 and 10% in water |
Ionosol products |
Ringer’s injection |
Ringer’s injection, lactated |
Sodium chloride 0.45 or 0.9% |
Sodium lactate (1/6) M |
Drug Compatibility
Compatible |
|---|
Amikacin sulfate |
Aminophylline |
Ascorbic acid injection |
Bleomycin sulfate |
Colistimethate sodium |
Erythromycin lactobionate |
Hydrocortisone sodium succinate |
Lidocaine HCl |
Methyldopate HCl |
Nafcillin sodium |
Penicillin G potassium |
Penicillin G sodium |
Polymyxin B sulfate |
Vitamin B complex with C |
Incompatible |
Amobarbital sodium |
Amphotericin B |
Dexamethasone sodium phosphate with lorazepam and metoclopramide HCl |
Iodipamide meglumine (% unspecified) |
Thiopental sodium |
Compatible |
|---|
Abciximab |
Acyclovir sodium |
Aldesleukin |
Amifostine |
Amsacrine |
Argatroban |
Azithromycin |
Aztreonam |
Bivalirudin |
Ciprofloxacin |
Cisplatin |
Cladribine |
Cyclophosphamide |
Cytarabine |
Dexmedetomidine HCl |
Docetaxel |
Doxorubicin HCl |
Doxorubicin HCl liposome injection |
Etoposide phosphate |
Famotidine |
Fenoldopam mesylate |
Fentanyl citrate |
Filgrastim |
Fluconazole |
Fludarabine phosphate |
Gallium nitrate |
Gemcitabine HCl |
Granisetron HCl |
Heparin sodium |
Hetastarch in lactated electrolyte injection (Hextend) |
Hydrocortisone sodium succinate |
Hydromorphone HCl |
Idarubicin HCl |
Linezolid |
Melphalan HCl |
Meperidine HCl |
Meropenem |
Methadone HCl |
Methotrexate sodium |
Morphine sulfate |
Ondansetron HCl |
Oxaliplatin |
Paclitaxel |
Pemetrexed disodium |
Piperacillin sodium–tazobactam sodium |
Potassium chloride |
Propofol |
Remifentanil HCl |
Sargramostim |
Sufentanil citrate |
Tacrolimus |
Teniposide |
Thiotepa |
Vinorelbine tartrate |
Vitamin B complex with C |
Incompatible |
Allopurinol sodium |
Amphotericin B cholesteryl sulfate complex |
Cefepime HCl |
Foscarnet sodium |
Lansoprazole |
ActionsActions
Blocks H1-receptor sites, thereby preventing the action of histamine on the cell.c
Suppresses flare and pruritus that accompany the endogenous release of histamine.c
Exhibits some activities common to anticholinergics, ganglionic and adrenergic blocking agents, local anesthetics, and antispasmodics.c
Antihistamines do not block the stimulating effect of histamine on gastric acid secretion, which is mediated by H2-receptors of the parietal cells.c
Effects on parkinsonian syndrome and drug-induced extrapyramidal reactions are apparently related to central anticholinergic effects.c
Advice to Patients
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Risk of drowsiness; avoid alcohol and use caution when driving, operating machinery, or engaging in other hazardous tasks.
When used for insomnia, consult a clinician if sleeplessness persists continuously for >2 weeks.
Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses. Importance of patients already receiving another CNS depressant (e.g., sedatives, tranquilizers) not undertaking self-medication without first consulting a clinician.
Importance of not using multiple diphenhydramine-containing preparations (either oral or topical) simultaneously because of risk of toxicity. (See Diphenhydramine Toxicity under Cautions.)
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
In response to concerns regarding the safety and efficacy of cough and cold preparations in young children, many nonprescription cough and cold preparations specifically formulated for infants have been voluntarily withdrawn from the US market. Therefore, some of the preparations described below may no longer be commercially available in the US.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Capsules | 25 mg* | Benadryl Allergy Kapseals | Pfizer |
Diphenhist | Rugby | |||
Diphenhydramine Hydrochloride Capsules | ||||
Genahist | Teva | |||
50 mg* | Diphenhydramine Hydrochloride Capsules | |||
Capsules, liquid-filled | 25 mg | Benadryl Dye-Free Allergy Liqui-Gels | Pfizer | |
50 mg | Nytol Quickgels Maximum Strength | Block | ||
Sleepinal Night-time Sleep Aid Softgels | Blairex | |||
Unisom SleepGels Maximum Strength | Pfizer | |||
Elixir | 12.5 mg/5 mL* | Diphen AF Elixir | Morton Grove | |
Diphenhydramine Hydrochloride Elixir | ||||
Genahist Elixir | Teva | |||
Hydramine Elixir | Alpharma, Moore, Teva | |||
Solution | 12.5 mg/5 mL* | AllerMax | Pfeiffer | |
Benadryl Allergy | Pfizer | |||
Benadryl Dye-Free Allergy Children’s | Pfizer | |||
Diphenhist | Rugby | |||
Diphenhydramine Solution | ||||
Hydramine Cough Syrup | Alpharma, Teva | |||
Tablets | 25 mg* | Diphenhist Captabs | Rugby | |
Diphenhydramine Hydrochloride Tablets | ||||
Genahist | Teva | |||
Miles Nervine Nighttime Sleep-Aid | Bayer | |||
Nytol QuickCaps Caplets | GlaxoSmithKline | |||
Sominex Nighttime Sleep Aid | GlaxoSmithKline | |||
50 mg | Compoz Nighttime Sleep Aid | Medtech | ||
Nighttime Sleep Aid | Rugby | |||
Twilite Caplets | Pfeiffer | |||
Tablets, chewable | 12.5 mg | Benadryl Allergy Chewables Children’s | Pfizer | |
Tablets, film-coated | 25 mg | Benadryl Allergy Ultratab | Pfizer | |
50 mg | AllerMax Caplets | Pfeiffer | ||
Simply Sleep Nighttime Sleep Aid Caplets | McNeil | |||
Sominex Caplets Maximum Strength | GlaxoSmithKline | |||
Parenteral | Injection | 50 mg/mL* | Benadryl | Pfizer |
Diphenhydramine Hydrochloride Injection |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | For solution | 38 mg/packet with 500 mg/packet Acetaminophen | Goody’s PM Powder | GlaxoSmithKline |
Solution | 25 mg/15 mL with Acetaminophen 500 mg/15mL | Tylenol PM Vanilla Liquid | McNeil | |
Tablets, film-coated | 38 mg with Acetaminophen 500 mg | Bayer PM Extra Strength Caplets | Bayer | |
Excedrin P.M. Caplets | Novartis | |||
Excedrin P.M. Geltabs | Novartis | |||
Excedrin P.M. Tablets | Novartis |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets, for solution | 38 mg with Aspirin 325 mg | Alka-Seltzer PM | Bayer |
Tablets, orally disintegrating | 19 mg (equivalent to Diphenhydramine Hydrochloride 12.5 mg) with Pseudoephedrine Hydrochloride 30 mg | Children’s Benadryl Allergy & Cold Fastmelt | Johnson & Johnson |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Solution | 12.5 mg/5 mL with Acetaminophen 160 mg/5 mL, and Phenylephrine Hydrochloride 2.5 mg/5 mL | Children's Tylenol Plus Cold and Allergy | McNeil |
12.5 mg/5 mL with Phenylephrine Hydrochloride 5 mg/5 mL | Children’s Benadryl Allergy & Sinus Liquid | Johnson & Johnson | ||
Tablets | 12.5 mg with Acetaminophen 325 mg and Phenylephrine Hydrochloride 5 mg | Benadryl Allergy & Cold Caplets | Johnson & Johnson | |
25 mg with Acetaminophen 325 mg and Phenylephrine Hydrochloride 5 mg | Benadryl Allergy & Sinus Headache Caplets Maximum Strength | Johnson & Johnson | ||
25 mg with Acetaminophen 500 mg | Tylenol PM Rapid Release Gels | McNeil | ||
Tylenol PM Extra Strength Geltabs | McNeil | |||
25 mg with Magnesium Salicylate 580 mg (equivalent to 467.2 mg of anhydrous magnesium salicylate) | Doan’s P.M. Extra Strength Caplets | Novartis | ||
Tablets, film-coated | 12.5 mg with Acetaminophen 325 mg and Phenylephrine Hydrochloride 5 mg | Benadryl Allergy & Cold Caplets Maximum Strength | Johnson & Johnson | |
Sudafed Multi-Symptom Severe Cold Caplets | Pfizer | |||
12.5 mg with Acetaminophen 500 mg | Percogesic Aspirin-Free Caplets Extra Strength | Medtech | ||
Tylenol Severe Allergy Caplets | McNeil | |||
25 mg with Acetaminophen 325 mg and Phenylephrine Hydrochloride 5 mg | Benadryl Severe Allergy & Sinus Headache Caplets | Johnson & Johnson | ||
Tylenol Allergy Multi-Symptom Nighttime Cool Burst Caplets | McNeil | |||
25 mg with Acetaminophen 500 mg | Tylenol PM Caplets | McNeil | ||
25 mg with Phenylephrine Hydrochloride 10 mg | Benadryl-D Allergy & Sinus | Johnson & Johnson | ||
50 mg with Acetaminophen 500 mg | Legatrin PM Caplets | Columbia |
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
DiphenhydrAMINE HCl 25MG Capsules (QUALITEST): 100/$12.99 or 200/$14.98
DiphenhydrAMINE HCl 50MG Capsules (MAJOR PHARMACEUTICALS): 100/$13.99 or 200/$16.98
Duratuss AC 12 15-12.5-15MG/5ML Suspension (VICTORY PHARMA): 473/$215.99 or 1419/$609.96
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
101. Parke-Davis. Benadryl (diphenhydramine hydrochloride injection) prescribing information. New York, NY; 2001 May.
102. Tang AW. A practical guide to anaphylaxis. Am Fam Physician. 2003; 68:1325-32. [PubMed 14567487]
103. Joint Task Force on Practice Parameters. The diagnosis and management of anaphylaxis. J Allergy Clin Immunol. 1998; 101:S465-528.
104. Crismon ML and Canales PL. Insomnia. In: American Pharmaceutical Association. Handbook of nonprescription drugs. 13th ed. Washington, DC: American Pharmaceutical Association; 2002;971-84.
105. Oderda GM and Shane-McWhorter L. Nausea and vomiting. In: American Pharmaceutical Association. Handbook of nonprescription drugs. 13th ed. Washington, DC: American Pharmaceutical Association; 2002;390-410.
106. Lee NP and Arriola EP. How to treat allergic rhinitis. West J Med. 1999; 171: 31-4. [PubMed 10483343]
107. Novartis Consumer Health, Inc. Excedrin PM (acetaminophen, diphenhydramine citrate) caplets patient information. From Novartis Consumer Health website. Accessed 2008 Feb 21.
108. McNeil-PPC, Inc. Benadryl Allergy & Cold (acetaminophen, diphenhydramine hydrochloride, phenylephrine hydrochloride) caplets patient information. From McNeil-PPC website. Accessed 2008 Feb 21.
109. McNeil-PPC, Inc. Tylenol PM (acetaminophen, diphenhydramine hydrochloride) rapid release gels, caplets, geltabs, and oral solution patient information. From McNeil-PPC website. Accessed 2008 Feb 21.
110. McNeil-PPC, Inc. Tylenol Allergy Multi-Symptom Nighttime (acetaminophen, diphenhydramine hydrochloride, phenylephrine hydrochloride) caplets patient information. From McNeil-PPC website. Accessed 2008 Feb 21.
111. GlaxoSmithKline Consumer Healthcare, LP. Goody's PM (acetaminophen, diphenhydramine citrate) powder patient information. From GlaxoSmithKline Consumer Healthcare website. Accessed 2008 Feb 22.
112. McNeil-PPC, Inc. Benadryl-D Allergy & Sinus (diphenhydramine hydrochloride, phenylephrine hydrochloride) tablets patient information. From McNeil-PPC website. Accessed 2008 Feb 25.
113. Bayer Healthcare LLC. Alka-Seltzer PM (aspirin, diphenhydramine citrate) effervescent tablets patient information. From Bayer Healthcare website. Accessed 2008 Feb 25.
114. McNeil-PPC, Inc. Children's Benadryl Allergy & Cold Fastmelt (diphenhydramine citrate, pseudoephedrine hydrochloride) tablets patient information. From McNeil-PPC website. Accessed 2008 Feb 25.
a. AHFS drug information 2003. McEvoy GK, ed. Diphenhydramine. Bethesda, MD: American Society of Health-System Pharmacists; 2003:24-8.
c. AHFS drug information 2003. McEvoy GK, ed. Antihistamines General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2003:2–9.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:535-44.
More Diphenhydramine Hydrochloride resources
- Diphenhydramine Hydrochloride Use in Pregnancy & Breastfeeding
- Drug Images
- Diphenhydramine Hydrochloride Drug Interactions
- Diphenhydramine Hydrochloride Support Group
- 58 Reviews for Diphenhydramine Hydrochloride - Add your own review/rating
- Banophen MedFacts Consumer Leaflet (Wolters Kluwer)
- Ben-Tann Suspension MedFacts Consumer Leaflet (Wolters Kluwer)
- Benadryl Consumer Overview
- Benadryl Cream MedFacts Consumer Leaflet (Wolters Kluwer)
- Benadryl Allergy Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Children's Allergy Prescribing Information (FDA)
- Diphen Advanced Consumer (Micromedex) - Includes Dosage Information
- Diphenhydramine Prescribing Information (FDA)
- Diphenhydramine MedFacts Consumer
No comments:
Post a Comment